Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Expenses (2016 - 2025)

Arrowhead Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $223.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 36.19% year-over-year to $223.2 million; the TTM value through Dec 2025 reached $790.4 million, up 25.77%, while the annual FY2025 figure was $731.1 million, 20.92% up from the prior year.
  • Operating Expenses reached $223.2 million in Q4 2025 per ARWR's latest filing, up from $212.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $223.2 million in Q4 2025 to a low of $61.0 million in Q1 2021.
  • Average Operating Expenses over 5 years is $133.4 million, with a median of $121.5 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: surged 100.1% in 2021, then dropped 11.02% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $90.8 million in 2021, then rose by 15.34% to $104.7 million in 2022, then surged by 33.83% to $140.1 million in 2023, then increased by 17.0% to $163.9 million in 2024, then soared by 36.19% to $223.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Operating Expenses are $223.2 million (Q4 2025), $212.4 million (Q3 2025), and $193.3 million (Q2 2025).